GSK343: Selective EZH2 Inhibitor for Epigenetic Cancer Research

Executive Summary: GSK343 is a nanomolar, cell-permeable inhibitor of histone methyltransferase EZH2, central to PRC2-mediated H3K27 trimethylation (APExBIO). It exhibits an IC₅₀ of 4 nM for EZH2 and 240 nM for EZH1, demonstrating high selectivity over other methyltransferases. GSK343 effectively reduces H3K27me3 in diverse cancer cell models and sensitizes tumor cells to other therapies. The compound is insoluble in water and ethanol but is soluble in DMF at ≥7.58 mg/mL. GSK343 is intended for in vitro use due to rapid clearance in animal models (Stern et al., 2024).

Biological Rationale

EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2). PRC2 methylates histone H3 at lysine 27 (H3K27), forming H3K27me3, a mark associated with transcriptional repression of genes such as RUNX3, FOXC1, and BRCA1 (APExBIO). Dysregulation of EZH2 is implicated in oncogenesis, stem cell maintenance, and tumor immune evasion (see this overview, which GSK343's article extends by benchmarking IC₅₀ and selectivity). Precise chemical inhibition of EZH2 enables mechanistic studies of chromatin regulation and helps identify epigenetic vulnerabilities in cancer models. The PRC2 pathway also intersects with DNA repair and telomerase (TERT) regulation, highlighting the importance of reliable EZH2 inhibitors in dissecting these networks (Stern et al., 2024, see this article for recent context on TERT regulation).

Mechanism of Action of GSK343

GSK343 is a competitive inhibitor of EZH2, targeting the S-adenosylmethionine (SAM) binding site. This prevents methyl transfer to H3K27, blocking formation of the H3K27me3 epigenetic mark. GSK343’s selectivity arises from its high affinity for EZH2 over other SAM-dependent methyltransferases, including DNMTs, MLL, PRMT, and SETMAR (this guide details protocol optimization; the current article adds specificity and in vitro boundaries). The compound also inhibits the closely related EZH1 isoform at higher concentrations (IC₅₀ = 240 nM). In vitro, GSK343 reduces global H3K27 trimethylation, leading to de-repression of PRC2 target genes, altered cell cycle progression, induction of apoptosis, and changes in autophagy in cancer cells. Notably, GSK343 does not significantly inhibit unrelated methyltransferases under standard conditions.

Evidence & Benchmarks

• GSK343 inhibits recombinant human EZH2 with an IC₅₀ of 4 nM (APExBIO product documentation, source).
• Cellular H3K27me3 is reduced in HCC1806 breast cancer cells with an IC₅₀ of 174 nM (APExBIO).
• GSK343 inhibits proliferation of LNCaP prostate cancer cells with an IC₅₀ of 2.9 μM (APExBIO, source).
• The compound shows minimal inhibition of DNMTs, MLL, PRMT, and SETMAR at 10 μM (APExBIO).
• GSK343 enhances the cytotoxic effect of sorafenib in HepG2 liver cancer cells in vitro (APExBIO).
• APEX2, a distinct DNA repair enzyme, modulates telomerase (TERT) expression by acting at repetitive elements, providing a context for chromatin-targeted strategies using EZH2 inhibitors (Stern et al., 2024).

Applications, Limits & Misconceptions

GSK343 is used primarily as an in vitro probe for EZH2-dependent chromatin regulation. It is suitable for interrogating PRC2 pathway function, mapping H3K27me3-dependent gene repression, and studying cancer cell fate decisions. GSK343 is not recommended for in vivo animal studies due to rapid clearance and suboptimal pharmacokinetics (see this article for a technical breakdown; the current piece adds cautionary guidance for in vivo use).

Common Pitfalls or Misconceptions

• GSK343 is not water- or ethanol-soluble; inappropriate solvent use may reduce assay reliability.
• In vivo efficacy is limited by high clearance; GSK343 is not suitable for animal dosing studies.
• While highly selective for EZH2, GSK343 also inhibits EZH1 at higher concentrations; isoform-specific effects require careful interpretation.
• DNA demethylation is not directly targeted; GSK343 does not inhibit DNMTs at standard research concentrations.
• Gene expression changes should be confirmed at the transcriptional and protein levels due to potential context-dependent effects.

Workflow Integration & Parameters

GSK343 is supplied as a solid and should be stored at -20°C (APExBIO). For cell-based assays, dissolve GSK343 in DMF at ≥7.58 mg/mL with gentle warming. Typical working concentrations range from 10 nM to 10 μM, depending on cell type and endpoint. Time-course experiments (24–72 hours) are recommended for robust H3K27me3 depletion. Include vehicle-only and positive control groups. Monitor cell viability (e.g., MTT/XTT), H3K27me3 levels (Western blot, ChIP), and target gene expression (qPCR). For combinatorial studies, GSK343 can be co-applied with agents such as sorafenib to assess synergy. APExBIO provides detailed protocols with the A3449 kit.

Conclusion & Outlook

GSK343 is a validated, highly selective, cell-permeable EZH2 inhibitor, enabling precise studies of PRC2-mediated chromatin regulation and epigenetic cancer mechanisms. Researchers should use GSK343 for in vitro mechanistic studies, taking care to account for EZH1 cross-reactivity and solubility constraints. The compound’s role is increasingly important as epigenetic research expands to encompass DNA repair, repetitive element regulation, and telomerase control in cancer and stem cell biology (Stern et al., 2024). For further reading on advanced applications and troubleshooting, see this article, which explores unique mechanistic insights and advanced workflows beyond the current summary.